"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)."

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Medica Scientia Innovation Research S.L.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

29 May 2025 → ongoing

Decision date (initial)

2025-04-08

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Merck Sharp & Dohme de España, S.A.

External identifiers

EU CT number

2024-513511-27-00

ClinicalTrials.gov

NCT06604858

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

To evaluate the pathological complete response (pCR) rate defined as the percentage of patients with ypT0/is, ypN0 at surgery based on local assessment.

Secondary objectives 3

1. To assess pCR rate according to PD-L1 status.
2. To evaluate residual cancer burden (RCB) and breast-conserving surgery (BCS) rate at surgery.
3. To evaluate the safety and toxicity of the treatment.

Conditions and MedDRA coding

HR-negative/HER2-negative resectable stage I TNBC.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 15

1. Written informed consent form (ICF) prior to beginning specific protocol procedures.
2. No prior chemotherapy, targeted therapy, and/or radiation therapy with therapeutic intent for this cancer.
3. Females of childbearing potential must have a negative urine or serum pregnancy test and be willing to use an adequate method of contraception according to study protocol during treatment and for at least 4 months after the last dose of pembrolizumab. Female patients must refrain from egg cell donation and breastfeeding during treatment with pembrolizumab and for at least 4 months after the last dose of pembrolizumab.
4. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use institution specified method(s) of contraception and must refrain from donating sperm or eggs during treatment with pembrolizumab and for at least 4 months after the last dose of pembrolizumab.
5. Patient has adequate bone marrow, liver, and renal function: I. Hematological: White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 9.0 g/dL (≥ 5.6 mmol/L). II. Hepatic: total bilirubin ≤ institutional upper limit of normal (ULN) (except for Gilbert’s syndrome); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times ULN. III. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
6. Patient must be accessible for treatment and follow-up.
7. Female or male patients ≥ 18 years of age.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
9. Histologically confirmed TNBC as defined by the most ASCO/CAP guidelines based on local laboratory results. Note: TNBC means tumors that have <1 percent expression of ER and PR as determined by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative
10. Tumor size between > 10 and 20 mm by mammogram and/or ultrasound, or ≤ 25 mm after biopsy by breast magnetic resonance imaging [MRI] as per local assessment. Note: Up to 25 mm of diameter using breast MRI is allowed if the MRI was performed within 2 weeks after the breast biopsy (due to tissue inflamation after the procedure).
11. Node-negative status by clinical exam and local radiological evaluation.
12. Bilateral tumors and/or multi-focal (e.g, 2, separate lesions in the same quadrant)/multi-centric (e.g, 2 separate lesions in different quadrants) tumors are allowed. The tumor with the most advanced T stage should be used to assess the eligibility and TNBC needs to be confirmed for each breast/focus. In these cases, both axillae need to be assessed for nodal involvement confirmation.
13. No evidence of metastatic disease based on radiological assessment according to institutional practices.
14. No previous definitive ipsilateral breast surgery for the current breast cancer.
15. Willingness to provide tumor tissue at baseline and at surgery and blood samples at the time of study entry (the closest time to the tumor biopsy), after two cycles of study treatment, and at the end of treatment, prior to surgery (the closest time to the tumor biopsy).

Exclusion criteria 18

1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137.
2. Has received prior systemic anti-breast cancer therapy including investigational agents within 4 weeks prior to allocation.
3. Has received prior taxane or platinum-based therapy.
4. Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
6. Has had an allogenic tissue/solid organ transplant.
7. Has a history of invasive malignancy within the last 5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.
8. Participation in an interventional clinical study within 4 weeks of first dose of study treatment.
9. Major surgical procedure or significant traumatic injury within 14 days prior to randomization or anticipation of need for major surgery within the course of the study treatment.
10. Has received a live vaccine within 30 days of first dose of study treatment.
11. Active autoimmune disease that has required systemic treatment in past 2 years, or ANY diagnosis of immunodeficiency or is receiving systemic steroid therapy (e.g, dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Replacement therapy (e.g, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
12. Current known infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
13. Other active uncontrolled infection at the time of enrollment.
14. Significant cardiovascular disease within the last 6 months OR congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA Class III or IV.
15. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
16. Other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, contraindicate patient participation.
17. Pregnancy or breastfeeding or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment.
18. Known hypersensitivity to the components of the study or its analogs.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. The efficacy will be evaluated by pCR rates concerning breast and lymph nodes (pCRBREAST+LYMPH NODE) in the overall population. pCR is defined as the absence of invasive carcinoma in both breast and lymph node tissue following completion of neoadjuvant treatment. The pCR rate will be calculated as the number of responders divided by the number of patients in the analysis set per 100.

Secondary endpoints 3

1. pCR rates will be calculated concerning breast and lymph nodes (pCRBREAST+LYMPH NODE) in patients with PD-L1 (+) tumors.
2. RCB score and BCS rate in the overall population at surgery
3. Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs) based on local Investigator assessment as per NCI-CTCAE v5.0.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Medica Scientia Innovation Research S.L.

Sponsor organisation

Medica Scientia Innovation Research S.L.

Address

Carrer De Pere IV 128 3rd Floor

City

Barcelona

Postcode

08005

Country

Spain

Scientific contact point

Organisation

Medica Scientia Innovation Research S.L.

Contact name

Alicia Garcia (Chief Scientific Officer)

Public contact point

Organisation

Medica Scientia Innovation Research S.L.

Contact name

Melissa Fernandez (International Trial Lead)

Locations

1 EU/EEA country · 11 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 10 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

8 submissions — initial application plus substantial / non-substantial modifications